Cold Spring Harbor Laboratory (CSHL) has licensed an artificial intelligence platform, developed by Epistemic AI, to accelerate discoveries related to cystic fibrosis (CF).
The platform, which also contains CF-specific resources, will help scientists in the lab accelerate their research by providing easy access to publications and clinical trials, and connection to multiple databases.
Its use can help to better understand the underlying relationships between diseases, their diagnosis, their treatments and their biological functions, and contribute to a better understanding of targeted therapies.
Epistemic AI Partners with the Boomer Esiason Foundation to Advance Cystic Fibrosis Research
In 2020, Epistemic AI partnered with the Boomer Esiason Foundation (BEF) – which focuses on fundraising, awareness and support for the CF community – to advance disease knowledge and care through using Epistemic AI’s unique knowledge discovery platform.
The foundation’s venture philanthropy model was key to providing CSHL with access to the platform.
“Working with BEF has been an incredible experience,” Epistemic AI CEO Stefano Pacifico said in a company press release.
“We anticipate that our partnership with Cold Spring Harbor Laboratory will prove extremely beneficial for cystic fibrosis research, while simultaneously providing CSHL researchers with actionable insights into cancer, genomics, and neuroscience,” Pacifico added.
Cystic fibrosis is a genetic disease characterized by the accumulation of abnormally sticky and thick mucus in various organs, including the lungs, pancreas, liver and intestines. It is caused by mutations in the CFTR gene, which provides the instructions to produce a channel protein of the same name that regulates the flow of water and salts in and out of cells.
Since the discovery of CFTR gene 32 years ago as the cause of cystic fibrosis, research into the disease has made significant progress. Research has focused on specific and rare mutations; improve CFTR protein function with CFTR modulators; complications such as infections, inflammation, loss of pancreatic function and gastrointestinal symptoms; and optimizing treatment regimens.
We hope that our partnership with Cold Spring Harbor Laboratory will prove extremely beneficial for cystic fibrosis research.
The Knowledge Discovery Platform approach is different from outdated methods involving keyword or semantic searching. It uses artificial intelligence tools to combine millions of documents and data points into a so-called knowledge map that “reflects relevant entities and relationships specific to a set of initial queries,” the company’s page says. Epistemic AI platform.
The information gathered creates a path that can quickly identify research gaps, find real-world evidence, uncover new connections, elucidate new hypotheses, and explore causal interactions and relationships.
The platform has CF-specific resources, such as CFTR variants, bacterial infections and antimicrobial resistant bacteria, such as Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli.
Using the new platform, CSHL researchers can explore large amounts of biomedical data quickly and effortlessly.
They can use the platform to access biomedical data from multiple sources, including published studies and reviews, data on genes, proteins, signaling pathways and cell types, symptoms of disease, therapies and patents, clinical trials, and clinical interpretation and guidelines.
CSHL is a leading international biomedical research institution, home to eight Nobel Laureates, employing nearly 600 scientists, students and technicians who contribute to scientific discoveries in the fields of cancer, neuroscience, plant biology and quantitative biology.
The platform will also be available to the more than 12,000 visiting scientists from around the world who participate in the institution’s meeting and course programs at campuses in Long Island and Suzhou, China. Many of these scientists have recently experimented with the platform with substantial success.
BEF was funded by Boomer Esiason, a former professional soccer player, and his wife Cheryl when their son, Gunnar Esiason, was diagnosed with CF in 1993. It raises funds ($150 million to date) and awareness at CF.
Through its partnership with BEF, Epistemic AI collaborates with universities, foundations, biopharmaceutical companies and hospitals to contribute to CF research and development.
The partners also host regular webinars to help patients understand current disease research trends and their impact on the management and treatment of CF.
#Platform #CSHL #Researchers #Access #Vast #Amounts #Data #Cold #Spring #Harbor #Lab #Licenses #Platform #Accelerate #Research #Cystic #fibrosis #news #today